Vera Therapeutics Inc
VERA20.310USD
-0.640-3.05%
Market hours （ET）Quotes delayed by 15 min
1.30BMarket Cap
LossP/E TTM
More Details of Vera Therapeutics Inc Company
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.
Company Info
Ticker SymbolVERA
Company nameVera Therapeutics Inc
IPO dateMay 14, 2021
CEODr. Marshall Fordyce, M.D.
Number of employees112
Security typeOrdinary Share
Fiscal year-endMay 14
Address2000 Sierra Point Parkway, Suite 1200
CityBRISBANE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94005
Phone16507700077
Websitehttps://veratx.com/
Ticker SymbolVERA
IPO dateMay 14, 2021
CEODr. Marshall Fordyce, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
Mr. David Louis Johnson
Mr. David Louis Johnson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Sean P. Grant
Mr. Sean P. Grant
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Kimball Hall
Ms. Kimball Hall
Independent Director
Independent Director
--
--
Dr. Robert M. (Rob) Brenner, M.D.
Dr. Robert M. (Rob) Brenner, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Marshall Fordyce, M.D.
Dr. Marshall Fordyce, M.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
287.51K
-9.77%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
135.56K
-89.68%
Dr. Andrew Cheng, M.D., Ph.D.
Dr. Andrew Cheng, M.D., Ph.D.
Independent Director
Independent Director
17.49K
--
Ms. Christy Oliger
Ms. Christy Oliger
Independent Director
Independent Director
--
--
Dr. Michael M. Morrissey, Ph.D.
Dr. Michael M. Morrissey, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. William D. Turner
Mr. William D. Turner
Chief Development Officer
Chief Development Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
Shareholders
Shareholders
Proportion
Avoro Capital Advisors LLC
8.94%
Longitude Capital Management Co., LLC
8.07%
T. Rowe Price Associates, Inc.
7.36%
BlackRock Institutional Trust Company, N.A.
5.62%
Deerfield Management Company, L.P.
5.25%
Other
64.76%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.41%
Hedge Fund
31.30%
Investment Advisor/Hedge Fund
30.28%
Venture Capital
12.85%
Corporation
3.00%
Research Firm
2.19%
Individual Investor
1.05%
Private Equity
0.75%
Pension Fund
0.23%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
380
74.98M
117.56%
-3.36M
2025Q1
382
72.82M
114.18%
-4.50M
2024Q4
363
73.64M
115.55%
+5.56M
2024Q3
344
64.32M
116.69%
-4.00M
2024Q2
326
63.69M
115.63%
-1.15M
2024Q1
280
61.43M
112.19%
+9.50M
2023Q4
210
49.91M
111.09%
+1.94M
2023Q3
190
48.72M
112.47%
-1.60M
2023Q2
180
47.50M
110.63%
+142.39K
2023Q1
161
46.72M
108.87%
+12.76M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Avoro Capital Advisors LLC
5.70M
8.94%
+91.90K
+1.64%
Mar 31, 2025
Longitude Capital Management Co., LLC
5.14M
8.07%
--
--
Oct 31, 2024
T. Rowe Price Associates, Inc.
4.70M
7.36%
+373.15K
+8.63%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.59M
5.62%
+33.98K
+0.96%
Mar 31, 2025
Deerfield Management Company, L.P.
3.35M
5.25%
+2.30M
+218.87%
Jun 06, 2025
Fidelity Management & Research Company LLC
3.23M
5.07%
+179.19K
+5.87%
Mar 31, 2025
The Vanguard Group, Inc.
2.91M
4.56%
-31.14K
-1.06%
Mar 31, 2025
Sofinnova Investments, Inc
2.79M
4.38%
--
--
Mar 31, 2025
Commodore Capital LP
2.56M
4.02%
+603.18K
+30.80%
Mar 31, 2025
Vestal Point Capital, LP
2.50M
3.92%
+1.43M
+132.56%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ALPS Medical Breakthroughs ETF
1.02%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
SPDR S&P Biotech ETF
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
ProShares Ultra Nasdaq Biotechnology
0.17%
Invesco Nasdaq Biotechnology ETF
0.17%
iShares Biotechnology ETF
0.12%
T Rowe Price Small-Mid Cap ETF
0.08%
iShares Russell 2000 Growth ETF
0.08%
Optimize Strategy Index ETF
0.07%
View more
ALPS Medical Breakthroughs ETF
Proportion1.02%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.94%
SPDR S&P Biotech ETF
Proportion0.43%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.25%
ProShares Ultra Nasdaq Biotechnology
Proportion0.17%
Invesco Nasdaq Biotechnology ETF
Proportion0.17%
iShares Biotechnology ETF
Proportion0.12%
T Rowe Price Small-Mid Cap ETF
Proportion0.08%
iShares Russell 2000 Growth ETF
Proportion0.08%
Optimize Strategy Index ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
